Evgen Pharma PLC (LON:EVG) has appointed a chief business officer as it focuses on potential partnering activities for its lead compound, SFX-01.
Taking the role from 1 April 2021 will be Helen Kuhlman PhD, who brings more than 20 years’ experience in government funding and equity investment together with scientific and business roles in public and private R&D-based biotechnology companies.
READ: Evgen Pharma outlines next steps for COVID trial after positive safety update
Dr Kuhlman joins Evgen from the Development Bank of Wales where she was responsible for equity investment in technology companies and for managing investments in the bank's portfolio companies.
Previous roles included being vice-president of corporate development at Chronos Therapeutics Ltd and at Innovate UK where she created and delivered the £180m Biomedical Catalyst competitive grant scheme funded by the UK government.
Dr Huw Jones, chief executive of Evgen, said: “We are delighted to appoint Helen to a key senior role within the company as we increase our focus on potential partnering activities for SFX-01.
“Helen will also have a key role within the team in providing a commercial focus on our indication selection, horizon scanning and competitor intelligence activities.”
SFX-01 is the company’s lead compound that has potential applications in cancers, inflammation and acute respiratory distress syndrome (ARDS), including COVID ARDS.